BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23908466)

  • 1. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
    Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
    Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.
    Valenzuela JO; Iclozan C; Hossain MS; Prlic M; Hopewell E; Bronk CC; Wang J; Celis E; Engelman RW; Blazar BR; Bevan MJ; Waller EK; Yu XZ; Beg AA
    J Clin Invest; 2009 Dec; 119(12):3774-86. PubMed ID: 19907075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
    Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
    Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
    Front Immunol; 2020; 11():593863. PubMed ID: 33324410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway.
    Sofi MH; Tian L; Schutt S; Khan I; Choi HJ; Wu Y; Bastian D; Ticer T; Kassir MF; Atilgan FC; Kim J; Sui X; Zivkovic A; Mehrotra S; O'Bryan JP; Stark H; Martin PJ; Ogretmen B; Yu XZ
    Leukemia; 2022 Jul; 36(7):1907-1915. PubMed ID: 35513703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice.
    Yu Y; Wang D; Liu C; Kaosaard K; Semple K; Anasetti C; Yu XZ
    Blood; 2011 Nov; 118(18):5011-20. PubMed ID: 21856864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.
    Betts BC; Locke FL; Sagatys EM; Pidala J; Walton K; Menges M; Reff J; Saha A; Djeu JY; Kiluk JV; Lee MC; Kim J; Kang CW; Tang CH; Frieling J; Lynch CC; List A; Rodriguez PC; Blazar BR; Conejo-Garcia JR; Del Valle JR; Hu CC; Anasetti C
    Front Immunol; 2018; 9():2887. PubMed ID: 30574153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.
    Nguyen H; Alawieh A; Bastian D; Kuril S; Dai M; Daenthanasanmak A; Zhang M; Iamsawat S; Schutt SD; Wu Y; Sleiman MM; Shetty A; Atkinson C; Sun S; Varela JC; Tomlinson S; Yu XZ
    Clin Cancer Res; 2020 Jul; 26(13):3481-3490. PubMed ID: 31919135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.
    Askew D; Pareek TK; Eid S; Ganguly S; Tyler M; Huang AY; Letterio JJ; Cooke KR
    Blood; 2017 Jan; 129(2):246-256. PubMed ID: 28064242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.
    Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D
    Front Immunol; 2022; 13():907673. PubMed ID: 35677056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
    Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
    Front Immunol; 2020; 11():181. PubMed ID: 32117306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
    Kumar S; Leigh ND; Cao X
    Front Immunol; 2018; 9():3003. PubMed ID: 30627129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
    Zhang J; Chen HM; Ma G; Zhou Z; Raulet D; Rivera AL; Chen SH; Pan PY
    Leukemia; 2019 Aug; 33(8):2078-2089. PubMed ID: 30737483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?
    Morris ES; MacDonald KP; Hill GR
    Blood; 2006 May; 107(9):3430-5. PubMed ID: 16380448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.